Hareth Nahi (@HarethNahi) profile picture

Hareth Nahi

@HarethNahi

Senior lecturer in hematology/multiple myeloma, Karolinska Institutet.

Joined June 2020
  • Tweets12
  • Following155
  • Followers58
Antibody Response to Covid-19 mRNA Vaccine (Comirnaty), in Myeloma Patients Treated with High-dose Melphalan and/or… pubmed.ncbi.nlm.nih.gov/3452…
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose...

Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose...

Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy

pubmed.ncbi.nlm.nih.gov
1
AddThis | Home authors.elsevier.com/c/1dYxY…
1
Nya rön ger hopp för behandling av multipelt myelom nyheter.ki.se/nya-ron-ger-ho…

Nya rön ger hopp för behandling av multipelt myelom

Forskare vid Karolinska Institutet har undersökt användningen av en låg dos av venetoklax, ett experimentellt läkemedel, för behandling av cancersjukdomen multipelt myelom hos patienter som fått...

nyheter.ki.se
Postdoctoral researcher in cancer biology ki.varbi.com/en/what:job/job…
Postdoctoral researcher in cancer biology

Postdoctoral researcher in cancer biology

Do you want to contribute to top quality medical research? Karolinska Institutet, Department of medicin, Huddinge The research group of Associate Prof. Hareth Nahi at the Department of Medicine, Cente

ki.varbi.com
Outcome of COVID-19 in multiple myeloma patients in relation to treatment pubmed.ncbi.nlm.nih.gov/3274…
Outcome of COVID-19 in multiple myeloma patients in relation to treatment - PubMed

Outcome of COVID-19 in multiple myeloma patients in relation to treatment - PubMed

COVID-19 has emerged as a global pandemic. Cancer patients have been reported to be at higher risk for adverse outcome of COVID-19. Studies are ongoing to decipher the risk factors and risk groups...

pubmed.ncbi.nlm.nih.gov
1
pubmed.ncbi.nlm.nih.gov/3274…
Outcome of COVID-19 in multiple myeloma patients in relation to treatment - PubMed

Outcome of COVID-19 in multiple myeloma patients in relation to treatment - PubMed

COVID-19 has emerged as a global pandemic. Cancer patients have been reported to be at higher risk for adverse outcome of COVID-19. Studies are ongoing to decipher the risk factors and risk groups...

pubmed.ncbi.nlm.nih.gov
1
3
#EHA - Interesting e-Poster Presentation: (EP1038) CORTICOSTERIOD TAPERING IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA RECEIVING SUBCUTANEOUS DARATUMUMAB (DARA SC): PART 3 OF THE OPEN-LABEL, MULTICENTER, PHASE 1B PAVO STUDY
2
#EHA - Interesting e-Poster Presentation: (EP914) AUTOLOGOUS NK CELL-BASED IMMUNOTHERAPY FOR MAINTENANCE TREATMENT OF MULTIPLE MYELOMA
2
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results … pubmed.ncbi.nlm.nih.gov/3247…
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple...

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple...

Janssen Research & Development.

pubmed.ncbi.nlm.nih.gov
3
Load more